PDS Biotechnology Corp — Director's Dealing 2016

Mar 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-03-11

Reporting Person: LOUGHLIN JAMES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-11	Common Stock	P	100	$7.575	Acquired	100	Indirect
2016-03-11	Common Stock	P	13	$7.627	Acquired	113	Indirect
2016-03-11	Common Stock	P	500	$7.639	Acquired	613	Indirect
2016-03-11	Common Stock	P	1107	$7.6385	Acquired	1720	Indirect
2016-03-11	Common Stock	P	600	$7.6385	Acquired	2320	Indirect
2016-03-11	Common Stock	P	500	$7.627	Acquired	2820	Indirect
2016-03-11	Common Stock	P	180	$7.627	Acquired	3000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	19625	Direct

Footnotes

F1: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.